Dexrazoxane: how it works in cardiac and tumor cells. Is it a prodrug or is it a drug?
about
The tell-tale heart: molecular and cellular responses to childhood anthracycline exposurePerturbation of microRNAs in rat heart during chronic doxorubicin treatmentVisnagin protects against doxorubicin-induced cardiomyopathy through modulation of mitochondrial malate dehydrogenase.Anthracycline toxicity to cardiomyocytes or cancer cells is differently affected by iron chelation with salicylaldehyde isonicotinoyl hydrazone.Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological preventionAnthracycline cardiotoxicity: from bench to bedside.Catalytic inhibitors of topoisomerase II differently modulate the toxicity of anthracyclines in cardiac and cancer cellsDihydromyricetin prevents cardiotoxicity and enhances anticancer activity induced by adriamycin.Cardiovascular complications of breast cancer therapy in older adultsQuantifying Drug-Induced Nanomechanics and Mechanical Effects to Single Cardiomyocytes for Optimal Drug Administration To Minimize Cardiotoxicity.Iron chelators with topoisomerase-inhibitory activity and their anticancer applications.Ataxia telangiectasia mutated in cardiac fibroblasts regulates doxorubicin-induced cardiotoxicity.Mechanisms of Cardiotoxicity of Cancer Chemotherapeutic Agents: Cardiomyopathy and Beyond.Synthetic and natural iron chelators: therapeutic potential and clinical useDexrazoxane-afforded protection against chronic anthracycline cardiotoxicity in vivo: effective rescue of cardiomyocytes from apoptotic cell deathTopoisomerase 2β: a promising molecular target for primary prevention of anthracycline-induced cardiotoxicity.Inhibition of Rac1 signaling by lovastatin protects against anthracycline-induced cardiac toxicity.The anticancer thiosemicarbazones Dp44mT and triapine lack inhibitory effects as catalytic inhibitors or poisons of DNA topoisomerase IIα.Role of hypoxia-inducible factors in the dexrazoxane-mediated protection of cardiomyocytes from doxorubicin-induced toxicity.Activation of miR-34a-5p/Sirt1/p66shc pathway contributes to doxorubicin-induced cardiotoxicity.Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation.The anthracyclines: when good things go bad.Mechanism-based engineering against anthracycline cardiotoxicity.Salubrious effects of dexrazoxane against teniposide-induced DNA damage and programmed cell death in murine marrow cells.The dual-targeted HER1/HER2 tyrosine kinase inhibitor lapatinib strongly potentiates the cardiac myocyte-damaging effects of doxorubicin.Comparative effects of doxorubicin and a doxorubicin analog, 13-deoxy, 5-iminodoxorubicin (GPX-150), on human topoisomerase IIβ activity and cardiac function in a chronic rabbit model.Molecular Mechanisms of the Cardiotoxicity of the Proteasomal-Targeted Drugs Bortezomib and Carfilzomib.Topoisomerases as anticancer targets.Highly potent visnagin derivatives inhibit Cyp1 and prevent doxorubicin cardiotoxicity.
P2860
Q26823592-D2D14902-CD3E-4070-BFBF-BAE0D15B1F26Q27335046-E98D02D3-C02E-4555-A334-64B4988A6B09Q30628082-E817A4D3-62B5-462E-9B39-234EAE780535Q33341069-CBE719EE-FFB9-4876-B4FF-F92A108A2F56Q33574045-859D9BB7-836A-4F9E-8E5A-1D0C7E4F6AB5Q34477415-94963947-1998-4D54-A507-6AEA89BEC93EQ35014803-E2EEF89D-95C4-4C63-ABAB-0696CC2F2B7AQ35550223-8F7B7DC8-64DB-4128-B869-9FA265F22D04Q35584686-5B07BB74-A892-4781-96CB-2C9984D7EC1EQ35887269-1665753E-B7CD-464A-A31C-92AC4A2445B3Q36568915-1265085B-17A2-452E-B41B-EFA4506E5F53Q36702443-2D34D2D9-0FE8-48CB-9667-242F981DAE40Q37038711-56EA701E-0C1E-41AF-9AC7-2F3F46EE8E1AQ37290073-C4000778-7F63-46CB-AF30-47E4C1E2C29BQ37330749-D0079D7D-CB0F-4F3F-857F-206424223ADDQ38148968-D9624AA2-F5B9-4AEE-8F0D-2A61607994BBQ38576068-D42DD311-280D-422E-A474-44A55DA03FF0Q39364743-63E36FD3-6229-4D70-99CC-4E690A916EF4Q39608341-24F6D1DE-6215-4F1F-B15C-BEFBB81346DBQ41717594-B92EFED7-4569-43D2-99F7-D4778EE3CA6AQ41896006-42FA4303-3030-41D4-89BA-DA0D153457ABQ42163160-9C5FDA29-11E3-429C-A218-CCBC5C515618Q42835370-9EB9D505-9A97-4A35-AFAF-E9A6A4A847BDQ43495742-944D5062-9F4E-4187-8E5E-E429EF2853FEQ44312601-6360FFA3-A32F-4F2E-8A2D-92990F792319Q48042771-38CF3816-6393-406E-BD76-39EB63304C5EQ48170012-351C002C-E266-47E0-B4C3-A0CCFCD16F68Q49832269-CAA2B2A2-5AA1-4723-9FB3-6DC418D28439Q50101800-385B9EBC-A620-4292-9EA0-FA76801BDCD3
P2860
Dexrazoxane: how it works in cardiac and tumor cells. Is it a prodrug or is it a drug?
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Dexrazoxane: how it works in cardiac and tumor cells. Is it a prodrug or is it a drug?
@en
type
label
Dexrazoxane: how it works in cardiac and tumor cells. Is it a prodrug or is it a drug?
@en
prefLabel
Dexrazoxane: how it works in cardiac and tumor cells. Is it a prodrug or is it a drug?
@en
P1476
Dexrazoxane: how it works in cardiac and tumor cells. Is it a prodrug or is it a drug?
@en
P2093
Brian B Hasinoff
Eugene H Herman
P2888
P304
P356
10.1007/S12012-007-0023-3
P577
2007-01-01T00:00:00Z